Spots Global Cancer Trial Database for polycythemia vera (pv)
Every month we try and update this database with for polycythemia vera (pv) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms | NCT04177576 | Myeloproliferat... | 2 additional tu... | 18 Years - | University Hospital, Bordeaux | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
| The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia | NCT02577926 | Polycythemia Ve... Essential Throm... | Ruxolitinib BAT | 18 Years - | RWTH Aachen University | |
| Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | NCT05421104 | Polycythemia Ve... | Ruxolitinib | 18 Years - 99 Years | Novartis | |
| Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms | NCT01816256 | Myeloproliferat... Polycythemia Ve... Essential Throm... Myelofibrosis (... | Upper gastroint... | - | University Health Network, Toronto | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | NCT04655092 | Polycythemia Ve... | P1101 (Ropegint... | 20 Years - | PharmaEssentia Japan K.K. | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
| Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | NCT05421104 | Polycythemia Ve... | Ruxolitinib | 18 Years - 99 Years | Novartis | |
| Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | NCT04182100 | Polycythemia Ve... | P1101 Low-dose aspiri... Phlebotomy | 20 Years - | PharmaEssentia Japan K.K. | |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | NCT04243122 | Myeloproliferat... Essential Throm... JAK2 Mutation Polycythemia Ve... Primary Myelofi... Venous Thromboe... | Apixaban 2.5 MG... Aspirin 81 mg | 18 Years - | Ottawa Hospital Research Institute | |
| A Study to Evaluate P1101 in Japanese PV Patients | NCT06002490 | Polycythemia Ve... | P1101 Low-dose aspiri... Phlebotomy | 18 Years - | PharmaEssentia Japan K.K. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
